TY - JOUR
T1 - Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection
AU - Marchegiani, G
AU - Todaro, V
AU - Boninsegna, E
AU - Negrelli, R
AU - Sureka, B
AU - Bonamini, D
AU - Salvia, R
AU - Manfredi, Riccardo
AU - Mucelli, Rp
AU - Bassi, C
PY - 2018
Y1 - 2018
N2 - ObjectivesTo assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX.MethodsPatients with either locally advanced (LA) and borderline resectable (BR) PDAC undergoing surgical exploration after FOLFIRINOX were retrospectively enrolled. Two pancreatic radiologists reviewed the CT blinded to the final outcome and assessed chemotherapy response and resectability. Patients were then divided into R0 resected (group A) and not resected/R1 resected (group B), which were compared.ResultsOf 59 patients included, 19 were defined as unresectable (32%), 33 borderline resectable (56%) and 7 resectable (12%) during the blind radiological evaluation after FOLFIRINOX. Once in a surgical setting, 27% were non-resectable, whereas 73% received surgical resection with a 70% R0 rate. Consequent sensitivity and specificity were 86% and 29%. At imaging review, significant decreases in longest tumour dimension were observed in both groups: from 32 mm (95% CI 15-55) to 21 (10-44) in group A and from 34 (18-70) to 26 (7-60) in group B, p < 0.05. However, a significant increase in tumour attenuation in all phases was only observed for R0 resected, from 52 HU (26-75) to 65 (35-92) in arterial phase (p < 0.001) and from 62 (36-96) to 78 (40-120) in the venous (p = 0.001).ConclusionAfter neoadjuvant FOLFIRINOX, CT predicted resectability with acceptable sensitivity but low specificity. The observation of increased tumour attenuation at CT scan after FOLFIRINOX treatment might represent a reliable predictor of R0 resection.Key Points center dot CT drives the assessment of PDAC resectability after FOLFIRINOX center dot CT predicts resectability with acceptable sensitivity but low specificity center dot Significant increase in tumour attenuation was only observed for R0 resected PDAC center dot Tumour attenuation after FOLFIRINOX represents a reliable predictor of R0 resection
AB - ObjectivesTo assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX.MethodsPatients with either locally advanced (LA) and borderline resectable (BR) PDAC undergoing surgical exploration after FOLFIRINOX were retrospectively enrolled. Two pancreatic radiologists reviewed the CT blinded to the final outcome and assessed chemotherapy response and resectability. Patients were then divided into R0 resected (group A) and not resected/R1 resected (group B), which were compared.ResultsOf 59 patients included, 19 were defined as unresectable (32%), 33 borderline resectable (56%) and 7 resectable (12%) during the blind radiological evaluation after FOLFIRINOX. Once in a surgical setting, 27% were non-resectable, whereas 73% received surgical resection with a 70% R0 rate. Consequent sensitivity and specificity were 86% and 29%. At imaging review, significant decreases in longest tumour dimension were observed in both groups: from 32 mm (95% CI 15-55) to 21 (10-44) in group A and from 34 (18-70) to 26 (7-60) in group B, p < 0.05. However, a significant increase in tumour attenuation in all phases was only observed for R0 resected, from 52 HU (26-75) to 65 (35-92) in arterial phase (p < 0.001) and from 62 (36-96) to 78 (40-120) in the venous (p = 0.001).ConclusionAfter neoadjuvant FOLFIRINOX, CT predicted resectability with acceptable sensitivity but low specificity. The observation of increased tumour attenuation at CT scan after FOLFIRINOX treatment might represent a reliable predictor of R0 resection.Key Points center dot CT drives the assessment of PDAC resectability after FOLFIRINOX center dot CT predicts resectability with acceptable sensitivity but low specificity center dot Significant increase in tumour attenuation was only observed for R0 resected PDAC center dot Tumour attenuation after FOLFIRINOX represents a reliable predictor of R0 resection
KW - Induction chemotherapy
KW - Multidetector computed tomography
KW - Neoplasm staging
KW - Pancreas ductal carcinoma
KW - Pancreatectomy
KW - Induction chemotherapy
KW - Multidetector computed tomography
KW - Neoplasm staging
KW - Pancreas ductal carcinoma
KW - Pancreatectomy
UR - http://hdl.handle.net/10807/171375
U2 - 10.1007/s00330-018-5410-6
DO - 10.1007/s00330-018-5410-6
M3 - Article
SN - 0938-7994
VL - 28
SP - 4265
EP - 4273
JO - European Radiology
JF - European Radiology
ER -
